Case report: a patient with pulmonary arterial hypertension transitioning from a PDE-5 inhibitor to Riociguat

被引：7

作者：

Poch, David S. ^{[1
]}

机构：

[1] Univ Calif San Diego, Div Pulm Crit Care & Sleep Med, San Diego, CA 92103 USA

来源：

BMC PULMONARY MEDICINE | 2016年 / 16卷

关键词：

Pulmonary arterial hypertension; sGC stimulators; Cyclic guanosine monophosphate; Chronic thromboembolic pulmonary hypertension;

D O I：

10.1186/s12890-016-0229-x

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

Background: We present here the case of a patient with pulmonary arterial hypertension and NYHA Class II symptoms who transitioned from PDE-5i therapy to riociguat. No protocol currently exists for transitioning between these PAH medications. Case presentation: A 59-year old male with a history of anorexigen use initially presented in 2008 and was felt to have non-operable small vessel disease. His care was transitioned to our center after insurance would not cover high-dose sildenafil in addition to ERA therapy. Conclusion: This case demonstrates a safe and successful transition from higher dose PDE-5is to riociguat with no interruption in therapy.

引用

页数：4

共 50 条

[1] Case report: a patient with pulmonary arterial hypertension transitioning from a PDE-5 inhibitor to Riociguat
David S. Poch
BMC Pulmonary Medicine, 16
[2] Transition From Pde-5 Inhibitors To Riociguat In Pulmonary Hypertension
Weir, N.
Brown, A. W.
DelaSantina, J.
King, C.
Lewis, D.
Franco-Palacios, D.
Nathan, S. D.
Shlobin, O. A.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2017, 195
[3] A Case of Chronic Heart Failure with Severe Pulmonary Hypertension Successfully Treated with PDE-5 Inhibitor
Takakura, Midori
Kato, Shingo
Azuma, Mai
Iinuma, Naoki
Kusakawa, Yuka
Shimizu, Satoru
Miki, Yuko
Nakachi, Tatsuya
Fukui, Kazuki
JOURNAL OF CARDIAC FAILURE, 2016, 22 (09) : S193 - S194
[4] Dasatinib-induced pulmonary arterial hypertension unresponsive to PDE-5 inhibition
Groeneveldt, Joanne A.
Gans, Steven J. M.
Bogaard, Harm J.
Vonk-Noordegraaf, Anton
EUROPEAN RESPIRATORY JOURNAL, 2013, 42 (03) : 869 - 870
[5] Riociguat For Patients With Chronic Thromboembolic Pulmonary Hypertension: Usefulness Of Transitioning From Phosphodiesterase Type 5 Inhibitor
Yamamoto, K.
Tanabe, N.
Suda, R.
Sasaki, A.
Matsumura, A.
Ema, R.
Kasai, H.
Kato, F.
Sekine, A.
Nishimura, R.
Jujo, T.
Sugiura, T.
Shigeta, A.
Sakao, S.
Tatsumi, K.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2017, 195
[6] Long-term therapy of interferon-alpha induced pulmonary arterial hypertension with different PDE-5 inhibitors: A case report
Jochmann N.
Kiecker F.
Borges A.C.
Hofmann M.A.
Eddicks S.
Sterry W.
Baumann G.
Trefzer U.
Cardiovascular Ultrasound, 3 (1)
[7] TREATMENT PATTERNS AMONG PATIENTS PRESCRIBED PDE-5 INHIBITOR MONOTHERAPY FOR PULMONARY HYPERTENSION
Yeaw, J.
Lickert, C.
Drake, W.
De, A. P.
Wade, R. L.
VALUE IN HEALTH, 2016, 19 (03) : A59 - A59
[8] Rationale and study design of the RESPITE trial: Riociguat clinical effects studied in pulmonary arterial hypertension (PAH) patients with insufficient treatment response to PDE-5 inhibitors (PDE-5i)
Hoeper, Marius
Benza, Raymond
Simonneau, Gerald
Klinger, James
Langleben, David
Naeije, Robert
Corris, Paul
EUROPEAN RESPIRATORY JOURNAL, 2015, 46
[9] Rationale and Study Design of the RESPITE Trial: Riociguat Clinical Effects Studied in Pulmonary Arterial Hypertension (PAH) Patients With Insufficient Treatment Response to PDE-5 Inhibitors (PDE-5i)
Hoeper, Marius
Benza, Raymond
Klinger, James
Simonneau, Gerald
Langleben, David
Naeije, Robert
Corris, Paul
CHEST, 2015, 148 (04)
[10] ARTERIAL METHEMOGLOBIN LEVEL PREDICTS THERAPEUTIC EFFECTIVENESS OF THE PDE-5 INHIBITORS IN PATIENTS WITH IDIOPATHIC PULMONARY ARTERIAL HYPERTENSION
Ono, Tomohiko
Tamura, Yuichi
Kawakami, Takashi
Kataoka, Masaharu
Sano, Motoaki
Satoh, Toru
Fukuda, Keiichi
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2011, 57 (14) : E1462 - E1462

← 1 2 3 4 5 →